Leniolisib: a novel treatment for activated phosphoinositide-3 kinase delta syndrome

被引：2
|
作者：
De, Surya K. [1 ,2 ]
机构：
[1] Conju Probe, San Diego, CA 92121 USA
[2] Bharath Univ, Dept Chem, Chennai, Tamil Nadu, India
来源：
FRONTIERS IN PHARMACOLOGY | 2024年 / 15卷
关键词：
idelalisib; duvelisib; copanlisib; alpelisib; leniolisib; phosphatidylinositol; 3-kinase; PI3K/AKT SIGNALING PATHWAY; PI3K-DELTA; DISCOVERY;
D O I：
10.3389/fphar.2024.1337436
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
(Figure presented.) Copyright © 2024 De.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Insulin reduces inflammation in endotoxemia by activation of phosphoinositide-3 kinase
    Schabbauer, G
    Tencati, M
    Holscher, T
    Mackman, N
    FASEB JOURNAL, 2005, 19 (05): : A1716 - A1717
  • [32] Development of Phosphoinositide-3 Kinase Pathway Inhibitors for Advanced Cancer
    Cleary, James M.
    Shapiro, Geoffrey I.
    CURRENT ONCOLOGY REPORTS, 2010, 12 (02) : 87 - 94
  • [33] Duvelisib: a phosphoinositide-3 kinase/inhibitor for chronic lymphocytic leukemia
    Vangapandu, Hima V.
    Jain, Nitin
    Gandhi, Varsha
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (05) : 625 - 632
  • [34] A novel function of eIF2α kinases as inducers of the phosphoinositide-3 kinase signaling pathway
    Kazemi, Shirin
    Mounir, Zineb
    Baltzis, Dionissios
    Raven, Jennifer F.
    Wang, Shuo
    Krishnamoorthy, Jothi-Latha
    Pluquet, Olivier
    Pelletier, Jerry
    Koromilas, Antonis E.
    MOLECULAR BIOLOGY OF THE CELL, 2007, 18 (09) : 3635 - 3644
  • [35] Liver disturbances in activated phosphoinositide 3-kinase δ syndrome
    Ben-Yakov, Gil
    Kapuria, Devika
    Marko, Jamie
    Cho, Min Ho
    Pittaluga, Stefania
    Kleiner, David Erwin
    Koh, Christopher
    Holland, Steven
    Uzel, Gulbu
    Heller, Theo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2018, 6 (05): : 1763 - 1765
  • [36] AMG 319, a Novel Inhibitor of Phosphoinositide-3 Kinase Delta (PI3Kd), Demonstrates Activity in Lymphoma Pre-Clinical Models
    Herko, Amanda
    Mavis, Cory
    Czuczman, Myron S.
    Hernandez, Francisco
    BLOOD, 2012, 120 (21)
  • [37] Activated phosphoinositide 3-dinase delta syndrome (APDS): An update
    Lougaris, Vassilios
    Cancrini, Caterina
    Rivalta, Beatrice
    Castagnoli, Riccardo
    Giardino, Giuliana
    Volpi, Stefano
    Leonardi, Lucia
    La Torre, Francesco
    Federici, Silvia
    Corrente, Stefania
    Cinicola, Bianca Laura
    Soresina, Annarosa
    Marseglia, Gian Luigi
    Cardinale, Fabio
    PEDIATRIC ALLERGY AND IMMUNOLOGY, 2022, 33 : 69 - 72
  • [38] Genetic Etiologies and Outcomes in Malignancy and Mortality in Activated Phosphoinositide 3-Kinase Delta Syndrome: A Systematic Review
    Buesch, Katharina
    Memmott, Heidi L.
    Mclaughlin, Heather M.
    Upton, Julia E. M.
    Harrington, Amanda
    ADVANCES IN THERAPY, 2025, 42 (02) : 752 - 771
  • [39] MORTALITY IN PATIENTS WITH ACTIVATED PHOSPHOINOSITIDE 3-KINASE DELTA SYNDROME (APDS), A SYSTEMATIC LITERATURE REVIEW (SLR)
    Busch, K.
    Memmott, H.
    McLaughlin, H.
    Harrington, A.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2023, 131 (05) : S63 - S63
  • [40] Overlapping Clinical Phenotypes in Patients with Primary Ciliary Dyskinesia or Activated Phosphoinositide 3-Kinase Delta Syndrome
    Shapiro, Adam J.
    Wu, Eveline Y.
    Morris-Rosendahl, Deborah J.
    Olivier, Kenneth N.
    Dell, Sharon D.
    Sagel, Scott D.
    Dutmer, Cullen M.
    Mosquera, Ricardo A.
    Rose, Markus
    O'Connor, Michael G.
    Ma, Chi A.
    Uzel, Gulbu
    Vece, Timothy J.
    Zariwala, Maimoona A.
    Knowles, Michael R.
    Leigh, Margaret W.
    Davis, Stephanie D.
    Ferkol, Thomas W.
    JOURNAL OF PEDIATRICS, 2025, 280
12345